Pancreatic cancer alters human CD4+ T lymphocyte function: A piece in the immune evasion puzzle

Pancreas

Volumn 40, Issue 7, 2011, Pages 1131-1137

  Fogar, Paola ^a   Basso, Daniela ^a   Fadi, Elisa ^b   Greco, Eliana ^b   Pantano, Giorgia ^b   Padoan, Andrea ^b   Bozzato, Dania ^b   Facco, Monica ^b   Sanzari, Maria Colomba ^a   Teolato, Sara ^b   Zambon, Carlo Federico ^a,b   Navaglia, Filippo ^a   Semenzato, Gianpietro ^b   Pedrazzoli, Sergio ^b   Plebani, Mario ^a,b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

CD69; cytokines; immunosurveillance

Indexed keywords

ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD96 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD; ANTIGENS, CD45; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; HEP G2 CELLS; HT29 CELLS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; PANCREATIC NEOPLASMS; TIME FACTORS; TUMOR ESCAPE;

EID: 80052968131     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31822077b8     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Loos M, Kleeff J, Friess H, et al. Approaches to localized pancreatic cancer. Curr Oncol Rep. 2008;10:212-219.
3. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897-909. (Pubitemid 37328891)
4. Farrow B, Albo D, Berger DH. The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res. 2008;149:319-328.
5. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71-78. (Pubitemid 38082155)
6. Condeelis J, Pollard JW. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263-266. (Pubitemid 43121975)
7. Abiatari I, DeOliveira T, Kerkadze V, et al. Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Mol Cancer Ther. 2009;8:1494-1504.
8. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004;4:941-952. (Pubitemid 39620069)
9. Bharadwaj U, Li M, Zhang R, et al. Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res. 2007;67:5479-5488. (Pubitemid 46997289)
10. Croci DO, Zacarías Fluck MF, Rico MJ, et al. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother. 2007;56:1687-1700. (Pubitemid 47313090)
11. Moo-Young TA, Larson JW, Belt BA, et al. Tumor-derived TGF-A mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J Immunother. 2009;32:12-21.
12. Fukunaga A, Miyamoto M, Cho Y, et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004;28:e26-e31.
13. Fogar P, Sperti C, Basso D, et al. Decreased total lymphocyte counts in pancreatic cancer: An index of adverse outcome. Pancreas. 2006;32:22-28. (Pubitemid 41803643)
14. Bronte V, Cingarlini S, Marigo I, et al. Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: A novel target for therapeutic intervention. Immunol Invest. 2006;35:327-357. (Pubitemid 44266779)
15. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137-148. (Pubitemid 39094044)
16. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat Rev Immunol. 2006;6:715-727. (Pubitemid 44453458)
17. Teng MW, Swann JB, Koebel CM, et al. Immune-mediated dormancy: An equilibrium with cancer. J Leukoc Biol. 2008;84:988-993.
18. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450:903-907. (Pubitemid 350231320)
19. Takahashi K, Toyokawa H, Takai S, et al. Surgical influence of pancreatectomy on the function and count of circulating dendritic cells in patients with pancreatic cancer. Cancer Immunol Immunother. 2006;55:775-784.
20. Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007;67:9518-9527. (Pubitemid 47535942)
21. Ryschich E, Nö tzel T, Hinz U, et al. Control of T-cellYmediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res. 2005;11:498-504. (Pubitemid 40116872)
22. Pandha H, Rigg A, John J, et al. Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines. Clin Exp Immunol. 2007;148:127-135. (Pubitemid 46364984)
23. Bellone G, Carbone A, Smirne C, et al. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol. 2006;177:3448-3460. (Pubitemid 44277866)
24. Tan MC, Goedegebuure PS, Belt BA, et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol. 2009;182: 1746-1755.
25. Von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med. 2000;343:1020-1034.
26. Adam JK, Odhav B, Bhoola KD. Immune responses in cancer. Pharmacol Ther. 2003;99:113-132. (Pubitemid 36700437)
27. Jiang H, Chess L. An integrated model of immunoregulation mediated by regulatory T cell subsets. Adv Immunol. 2004;83:253-288. (Pubitemid 38657643)
28. Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12:5423-5434. (Pubitemid 44497257)
29. Liyanage UK, Goedegebuure PS, Moore TT, et al. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother. 2006;29:416-424. (Pubitemid 44288954)
30. Hinz S, Pagerols-Raluy L, Oberg HH, et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res. 2007;67:8344-8350. (Pubitemid 47395173)
31. Nummer D, Suri-Payer E, Schmitz-Winnenthal H, et al. Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma. J Natl Cancer Inst. 2007;99:1188-1199. (Pubitemid 47233069)
32. Tassi E, Gavazzi F, Albarello L, et al. Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients. J Immunol. 2008;181:6595-6603.
33. Viehl CT, Moore TT, Liyanage UK, et al. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancerYbearing mice. Ann Surg Oncol. 2006;13: 1252-1258. (Pubitemid 44440427)
34. Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654-2666. (Pubitemid 41817714)
35. Galon J, Fridman WH, Pagès F. The adaptive immunologic microenvironment in colorectal cancer: A novel perspective. Cancer Res. 2007;67:1883-1886. (Pubitemid 46424201)
36. Lyman MA, Aung S, Biggs JA, et al. A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL. J Immunol. 2004;172:6558-6567. (Pubitemid 38669090)
37. Shi Y, Liu CH, Roberts AI, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: What we do and don't know. Cell Res. 2006;16:126-133. (Pubitemid 43247967)
38. Morse MA, Hall JR, Plate JM. Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer. Expert Opin Biol Ther. 2009;9:331-339.
39. Zhu J, Paul WE. CD4 T cells: Fates, functions, and faults. Blood. 2008;112:1557-1569.
40. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9: 162-174.
41. Han Y, Guo Q, Zhang M, et al. CD69+ CD4+ CD25j T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-A1. J Immunol. 2009;182: 111-120.